Optimal gene therapy network: Enhancing cancer classification through advanced AI-driven gene expression analysis
e-Prime - Advances in Electrical Engineering, Electronics and Energy, ISSN: 2772-6711, Vol: 7, Page: 100449
2024
- 1Citations
- 12Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Most Recent News
Research from GIET University Yields New Study Findings on Cancer Gene Therapy (Optimal gene therapy network: Enhancing cancer classification through advanced AI-driven gene expression analysis)
2024 MAR 08 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Daily -- Fresh data on cancer gene therapy are presented
Article Description
Gene therapy is an advanced medical approach that aims to find solutions for various cancers by identifying optimal gene expressions. In this context, computer-aided detection of gene expressions becomes a research challenge, where artificial intelligence methods are employed to classify cancer types. However, traditional machine learning models must be improved for accurately classifying cancers, leading to unsatisfactory quantitative performance. Therefore, this work implemented the optimal gene therapy network (OGT-Net) for identifying the different types of cancers from the gene expression sequences. Initially, the dataset pre-processing operation normalizes the dataset, which maintains the uniform nature of all records in the dataset. Then, the light gradient boosting model (LGBM) extracts the correlated features from the pre-processed dataset, which contains the relationship among the pre-processed gene expression data. In addition, interrupt-based Harris Hawk optimization (IHHO) extracts the optimal features from LGBM data, decreasing the total number of features by removing redundant gene sequences. Then, a customized deep learning convolution neural network (DLCNN) is used to categorize diseases using gene expression datasets based on lymphography, colon, lung, ovarian, and prostate cancers. The simulation results reveal that the proposed OGT-Net improved performance on various datasets compared to existing approaches, with an average accuracy of 91.128 %, precision of 90.836 %, recall of 91.25 %, and F1-score of 90.7 %.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2772671124000317; http://dx.doi.org/10.1016/j.prime.2024.100449; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85185777864&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/S2772671124000317; https://dx.doi.org/10.1016/j.prime.2024.100449
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know